Published on in Vol 22, No 8 (2020): August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/21778, first published .
Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial

Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial

Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor–Driven Virtual Diabetes Clinic: Prospective Trial

Journals

  1. Edelman S, Cavaiola T, Boeder S, Pettus J. Utilizing continuous glucose monitoring in primary care practice: What the numbers mean. Primary Care Diabetes 2021;15(2):199 View
  2. Galindo R, Parkin C, Aleppo G, Carlson A, Kruger D, Levy C, Umpierrez G, McGill J. What's Wrong with This Picture? A Critical Review of Current Centers for Medicare & Medicaid Services Coverage Criteria for Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2021 View
  3. Jackson M, Ahmann A, Shah V. Type 2 Diabetes and the Use of Real-Time Continuous Glucose Monitoring. Diabetes Technology & Therapeutics 2021;23(S1):S-27 View
  4. Ang I, Tan K, Tan C, Tan C, Kwek J, Tay J, Toh S. A Personalized Mobile Health Program for Type 2 Diabetes During the COVID-19 Pandemic: Single-Group Pre–Post Study. JMIR Diabetes 2021;6(3):e25820 View
  5. Kruger D, Anderson J. CGM is a Tool, Not a Reward. Unjustified Insurance Coverage Criteria Limit Access to CGM. Diabetes Technology & Therapeutics 2021 View
  6. Gavin J, Bailey C. Real-World Studies Support Use of CGM in Type 1 and Type 2 Diabetes Independently of Treatment Regimen. Diabetes Technology & Therapeutics 2021 View